TRIC-I-HFHot Line 7Structural Heart

Tricuspid Valve Intervention in Patients with Heart Failure

Tricuspid valve intervention in patients with heart failure

Presenting authorJörg HausleiterInterventional / Structural Cardiology · Ludwig Maximilians University, Munich, Germany

Prof. Dr. med. Jörg Hausleiter is Professor of Medicine and Deputy Clinic Director of the Medical Clinic and Polyclinic I at LMU Klinikum in Munich, Germany. He is an interventional cardiologist whose research and clinical work focus on transcatheter therapies for mitral and tricuspid regurgitation as well as cardiac imaging. He previously completed a research fellowship at Cedars-Sinai Medical Center and held positions at the German Heart Center Munich.

Overview

Pending tricuspid intervention trial in HF leaves open outcome benefit; RCT data needed before practice consideration.

Key result

Tricuspid valve intervention in patients with heart failure is the subject of a late-breaking trial at ESC Congress 2026, with results currently pending.

Discussion

Expert reaction lands here the moment TRIC-I-HF reports.

Expert takes

TRIC-I-HF (TRICuspid Intervention in Heart Failure) is an investigator-initiated, prospective, multicenter, randomized controlled trial conducted across 29 German heart valve centers evaluating whether transcatheter tricuspid valve intervention (TTVI) plus optimal medical therapy reduces mortality and heart failure hospitalizations compared to OMT alone in patients with severe tricuspid regurgitation and manifest right-sided heart failure. Results are scheduled for presentation at ESC Congress 2026 by Jörg Hausleiter, with key subgroup results also planned for TCT 2026. The source material contains very limited direct expert quotes about this specific trial.

Tomasz Guzik

Chair, ESC Congress Program Committee

“Randomized controlled trials are the cornerstone of evidence-based cardiovascular medicine because they provide the highest level of evidence to guide clinical practice. This year, ESC Congress received a record number of submissions of late-breaking clinical trials, reflecting the remarkable pace of innovation across cardiology. We rigorously selected the studies with the greatest scientific quality and potential clinical impact.”

European Society of Cardiology

Key Points

Tricuspid valve intervention is evaluated as an emerging structural heart therapy for patients presenting with chronic heart failure symptoms.
Trial protocol presented at the ESC Congress 2026 session evaluates the therapeutic potential of tricuspid valve intervention in heart failure.
Clinical findings remain pending as this late-breaking trial aims to clarify the clinical benefits of tricuspid valve intervention strategies.

Structured PICO

Does tricuspid valve intervention improve outcomes in patients with heart failure?

Population

Patients with heart failure

Intervention

Tricuspid valve intervention

Late-breaking trial announcement for tricuspid valve intervention in heart failure with results pending.

Main Result

Absolute Event Rate: 0% vs 0%

AIに質問

Bookmark

View Full Paper